This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • JNJ 4528 showed early, deep and durable responses ...
News

JNJ 4528 showed early, deep and durable responses in heavily pretreated patients with multiple myeloma.Janssen Pharmaceutical Companies.

Read time: 1 mins
Last updated:22th May 2020
Published:21th May 2020
Condition: Multiple Myeloma
Type: drug
Register now for full access to medthority.com